Table 2.
Clinico‐biological features of the 36 patients with SMZL‐T at the time of transformation.
| Characteristics | N | n (%) |
|---|---|---|
| Age >60 years | 36 | 25 (69) |
| Females | 36 | 23 (64) |
| B symptoms | 35 | 24 (69) |
| ECOG Performance Status ≥2 | 35 | 11 (69) |
| Ann Arbor Stage III–IV | 36 | 33 (92) |
| Bulky disease (>7 cm) in lymph nodes | 30 | 8 (27) |
| Haemoglobin level <100 g/l | 36 | 31 (86) |
| Platelet count <100 × 109/l | 36 | 5 (14) |
| Raised LDH | 33 | 23 (70) |
| Raised B2M | 28 | 22 (79) |
| IPI high risk | 35 | 29 (83) |
| Transformation time | 36 | |
| At diagnosis | 5 (14) | |
| During follow‐up* | 31 (86) |
B2M, β2‐microglobulin; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.
*
Sites of transformation: 17 in one site: 11 in lymph node, four in bone marrow, one in spleen and one in nasal septum; 14 in more than one site: lymph node and bone marrow in six (four of them with also extra‐nodal involvement), lymph node and pleural effusion in three, spleen, liver, pleural effusion and ascites in two, lymph node and lip in one, spleen and bone marrow in one, and spleen, bone marrow and lymph node in one.